CD79A and COVID-19: On the other hand, the general population today has had recurrent exposures over time to various COVID-19 variants; and therefore, the immune system in the upper respiratory tract mucosa has high baseline levels of secretory IgA, resulting in less dramatic responses to new antigenic exposures.